←PHRPhreesiaOur view: NeutralFull analysisעברית
Updated 16 Nov 2026
The company · 1 · Who is this company?

Phreesia runs the check-in screen at the doctor's

About 4,514

practices use it

About 180 million

visits a year on it

About one in six

US doctor visits

Patients check in on Phreesia's tablet: insurance captured, forms signed, the bill worked out and paid, a health questionnaire answered.

The company · 2 · What exactly does it sell?

Three buyers pay for the same screen

Each $1 of sales, second quarter of fiscal 2027
41%30%30%
Software for practicesHandling patient paymentsDrug-company messages

Practices pay for the software, patients' payments earn a fee, and drug companies pay to show messages on the screen.

The company · 3 · How does it make money?

One check-in screen, three ways to earn

About $106,467a year from each client
$4,873Mof patient payments handled, fiscal 2026
29%of sales from drug advertising

Drug companies pay so well for the screen that Phreesia can charge practices less than a software-only rival. Each contract runs a year.

Is it a good business? · 4 · What gives it an edge?

It owns minutes nobody else can buy

About $106,467

a year from each client

+7%

clients last year

An advertiser can reach patients in the waiting room only through whoever runs the check-in.

Is it a good business? · 5 · What is the catch?

Each buyer has somewhere else to go

+15.5%Weave's growth, practice software
+18.1%Waystar's growth, billing
-29.8%OptimizeRx's sales, drug messages

Listed rivals: WEAV · WAY · OPRX · SYF

Phreesia's own software line shrank while listed rivals grew.

Is it a good business? · 6 · What does its record show?

Cost cuts, not growth, made it profitable

Sales, $M
213.2
280.9
356.3
419.8
480.6
507.8
Jan 2022Jan 2023Jan 2024Jan 2025Jan 2026last 12 mo
Costs49.9¢ to 20.9¢sales and marketing per $1, fiscal 2022 to 2026
Software$219.5Msubscriptions, fiscal 2026
Own growthAbout 4.4%growth last quarter without AccessOne

Cutting staff and sales spending pulled it from heavy losses to a small profit.

Is it a good business? · 7 · How much room is there to grow?

Patients paid $556.6B of their own bills

$556.6BAmericans' own health bills, 2024
About $95.0Bpaid through doctors' offices
About 5%passing through Phreesia

It handled $4,873M of patient payments in fiscal 2026.

Is it a good business? · 8 · Who is in charge?

The co-founder still runs it

2005Chaim Indig co-founded it
About 5%owned by insiders
About 14%held by Pale Fire Capital

The bonus rides on sales and a profit figure that leaves out pay in shares.

The story right now · 9 · Why did drug advertising stall?

Washington pressed drug advertisers, and budgets shrank

September 2025Washington pressed drug advertisers
-29.8%a rival's drug-message sales
+8.9%Phreesia's advertising, latest quarter

Drug companies pay to reach patients just before they see a doctor. When regulators pressed them over advertising, the whole sector's budgets shrank.

The story right now · 10 · Where is the growth coming from?

A bought business hides a shrinking core

  1. Phreesia buys AccessOnePatient payment plans.
  2. Total sales rise 10.4%Mostly the purchase.
  3. Software shrinks 1.9%Two quarters running.
  4. Lending adds risk$419M of payment plans.

The market has priced the advertising stall, but not yet the software shrinking while rivals grow.

The story right now · 11 · What changed lately?

Sales rose 10.4% while software fell 1.9%

$129.5Mquarterly sales
+8.9%advertising
-1.9%software subscriptions

Mixed quarter

Most growth came from AccessOne, the bought lending business. Management gave no customer retention figures. The price is now far below its six-year average per dollar of sales.

The story right now · 12 · What is everyone arguing about?

Is the shrinking software chosen or forced?

Many investors think

Drug advertising is permanently smaller

We think

Right on ads; the shrinking software is not priced yet

Against us: management may have cut software prices to win more from payments and advertising. Subscription growth returning would prove it.

The price and our view · 13 · What is a share worth?

No single value here: profit after share pay is too thin

Forecasts show little profit after share pay, so a value built on earnings would rest on a guess. We judge it on the business events below instead.

The price and our view · 14 · How could we be wrong?

Drug ads, software rivals and share pay

Drug advertisingBiggest

29% of sales, sold a year at a time.

Software losing to rivalsShowing now

Two quarters of decline.

Lending riskWatch

About $419M of patient payment plans.

Chosen or forcedUnknown

No retention figures given.

New shares for staff take close to a third of the cash the business produces each year.

The price and our view · 15 · How will we know?

December shows whether software stops shrinking

Subscription revenue flat or up, advertising upGood sign
Shares issued to staff well below 3.4% a yearWe turn positive
Practices stop growing, purchases left outWe turn negative
DEC 202614

Third-quarter fiscal 2027 results, 14 December. Companies report every three months; each report is a test of the story.

Our view moves on these business events, not on a price line, since we put no single value on a share here.

The price and our view · 16 · So, what do we think?

It owns the waiting room, but the software shrinks

NeutralMedium conviction

Phreesia runs the check-in tablet at about one in six US doctor visits. The shares look cheap on cash, but advertising stalled, software is shrinking and growth came from a lending business it bought. Neutral.

↑ ↓ to move · C for contents